α-干扰素治疗骨髓纤维化：一例报告

alpha-Interferon in myelofibrosis: a case report.

作者信息

Dalla K P, Zeigler Z R, Shadduck R K

机构信息

Western Pennsylvania Cancer Institute, Western Pennsylvania Hospital, Pittsburgh 15224.

出版信息

Br J Haematol. 1994 Mar;86(3):654-6. doi: 10.1111/j.1365-2141.1994.tb04802.x.

DOI:10.1111/j.1365-2141.1994.tb04802.x

PMID:8043450

Abstract

A patient with advanced myeloid metaplasia was treated with alpha-interferon (29 months) with a remarkable response. He had anaemia, thrombocytopenia and hepatosplenomegaly with infarction. The initial bone marrow showed replacement with fibrosis with no evident haemopoietic cells. Post-therapy, the patient became asymptomatic, transfusion independent and had normal blood counts. The repeat bone marrow was 30% cellular with 1 + reticulin and no fibrosis. Treatment was well tolerated without appreciable side-effects. These results indicate that prolonged therapy with alpha-interferon can improve haemopoiesis and reverse marrow fibrosis.

摘要

一名晚期骨髓化生患者接受了α-干扰素治疗（29个月），反应显著。他有贫血、血小板减少以及伴有梗死的肝脾肿大。初始骨髓显示被纤维化替代，无明显造血细胞。治疗后，患者无症状，无需输血，血细胞计数正常。复查骨髓有30%的细胞成分，网状纤维1级，无纤维化。治疗耐受性良好，无明显副作用。这些结果表明，长期使用α-干扰素治疗可改善造血并逆转骨髓纤维化。